Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2001-06-13
2002-12-31
Vollano, Jean F. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S051000, C546S001000, C548S400000, C549S200000
Reexamination Certificate
active
06500863
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to novel sulfonamide substituted diphenyl urea compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO&agr;, GRO&bgr;, GRO&ggr;, NAP-2 and ENA-78 mediated diseases.
BACKGROUND OF THE INVENTION
Many different names have been applied to Interleukin-8 (IL-8), such as neutrophil attractant/activation protein-1 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor. Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells. It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-1&agr;, IL-1&bgr;or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP. M. Baggiolini et al.,
J. Clin. Invest.
84, 1045 (1989): J. Schroder et al,
J. Immunol.
139, 3474 (1987) and
J. Immunol.
144, 2223 (1990); Strieter, et al.,
Science
243, 1467 (1989) and
J. Biol. Chem.
264, 10621 (1989); Cassatella et al.,
J. Immunol.
148, 3216 (1992).
GRO&agr;, GRO&bgr;, GRO&ggr;and NAP-2 also belong to the chemokine family. Like IL-8 these chemokines have also been referred to by different names. For instance GRO&agr;, &bgr;, &ggr; have been referred to as MGSA&agr;, &bgr; and &ggr; respectively (Melanoma Growth Stimulating Activity), see Richmond et al.,
J. Cell Physiology
129, 375 (1986) and Chang et al.,
J. Immunol
148, 451 (1992). All of the chemokines of the &agr;-family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor (CXCR2). IL-8, GRO&agr;, GRO&bgr;, GRO&ggr;, NAP-2, and ENA-78 stimulate a number of functions in vitro. They have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GRO&agr; have demonstrated T-lymphocytes, and basophilic chemotactic activity. In addition IL-8 can induce histamine release from basophils from both normal and atopic individuals. GRO-&agr; and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis. This may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many known diseases are characterized by massive neutrophil infiltration. As IL-8, GRO&agr;, GRO&bgr;, GRO&ggr;and NAP-2 promote the accumulation and activation of neutrophils, these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al.,
FEBS Lett.
307, 97 (1992); Miller et al.,
Crit. Rev. Immunol.
12, 17 (1992); Oppenheim et al.,
Annu. Rev. Immunol.
9, 617 (1991); Seitz et al.,
J. Clin. Invest.
87, 463 (1991); Miller et al.,
Am. Rev. Respir. Dis.
146, 427 (1992); Donnely et al.,
Lancet
341, 643 (1993). In addition the ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis, Strieter et al.,
Science
258, 1798 (1992).
In vitro, IL-8, GRO&agr;, GRO&bgr;, GRO&ggr; and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the IL-85&bgr;receptor (CXCR2). Thomas et al.,
J. Biol. Chem.
266, 14839 (1991); and Holmes et al.,
Science
253, 1278 (1991). The development of non-peptide small molecule antagonists for members of this receptor family has precedent. For a review see R. Freidinger in:
Progress in Drug Research, Vol.
40, pp. 33-98, Birkhauser Verlag, Basel 1993. Hence, the IL-8 receptor represents a promising target for the development of novel anti-inflammatory agents.
Two high affinity human IL-8 receptors (77% homology) have been characterized: IL-8R&agr;, which binds only IL-8 with high affinity, and IL-8R&bgr;, which has high affinity for IL-8 as well as for GRO&agr;, GRO&bgr;, GRO&ggr; and NAP-2. See Holmes et al., supra; Murphy et al.,
Science
253, 1280 (1991); Lee et al.,
J. Biol. Chem.
267, 16283 (1992); LaRosa et al.,
J. Biol. Chem.
267, 25402 (1992); and Gayle et al.,
J. Biol. Chem.
268, 7283 (1993).
There remains a need for treatment, in this field, for compounds, which are capable of binding to the IL-8&agr; or &bgr; receptor. Therefore, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil and T-cells subsets into the inflammatory site) would benefit by compounds, which are inhibitors of IL-8 receptor binding.
SUMMARY OF THE INVENTION
This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8a or b receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8.
This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
The present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.
Compounds of Formula (I) useful in the present invention are represented by the structure:
wherein
R
b
is independently hydrogen, NR
6
R
7
, OH, OR
a
, C
1-5
alkyl, aryl, arylC
1-4
alkyl, aryl C
2-4
alkenyl; cycloalkyl, cycloalkyl C
1-5
alkyl, heteroaryl, heteroarylC
1-4
alkyl, heteroarylC
2-4
alkenyl, heterocyclic, heterocyclic C
1-4
alkyl, or a heterocyclic C
2-4
alkenyl moiety, all of which moieties may be optionally substituted one to three times independently by halogen; nitro; halosubstituted C
1-4
alkyl; C
1-4
alkyl; amino, mono or di-C
1-4
alkyl substituted amine; OR
a
; C(O)R
a
; NR
a
C(O)OR
a
; OC(O)NR
6
R
7
; hydroxy; NR
9
C(O)R
a
; S(O)
m
, R
a
; C(O)NR
6
R
7
; C(O)OH; C(O)OR
a
; S(O)
t
NR
6
R
7
; NHS(O)
t
R
a
. Alternatively, the two R
b
substituents can join to form a 3-10 membered ring, optionally substituted and containing, in addition to optionally substituted C
1-4
alkyl, independently, 1 to 3 NR
a
, O, S, SO, or S
2
moities which can be optionally unsaturated;
R
a
is an alkyl, aryl, arylC
1-4
alkyl, heteroaryl, heteroaryl C
1-4
alkyl, heterocyclic, COOR
a
′, or a heterocyclic C
1-4
alkyl moiety, all of which moieties may be optionally substituted;
R
a
′ is an alkyl, aryl, arylC
1-4
alkyl, heteroaryl, heteroaryl C
1-4
alkyl, heterocyclic or a heterocyclic C
1-4
alkyl moiety, all of which moieties may be optionally substituted;
m is an integer having a value of 1 to 3;
m′ is 0, or an integer having a value of 1 or 2;
n is an integer having a value of 1 to 3;
q is 0, or an integer having a value of 1 to 10;
t is 0, or an integer having a value of 1 or 2;
s is an integer having a value of 1 to 3;
R
1
is independently selected from hydrogen, halogen, nitro, cyano, C
1-10
alkyl, halosubstituted C
1-10
alkyl, C
2-10
alkenyl, C
1-10
alkoxy, halosubstituted C
1-10
alkoxy, azide, S(O)
t
R
4
, (CR
8
R
8
)q S(O)
t
R
4
, hydroxy, hydroxy substituted C
1-4
alkyl, aryl, aryl C
1-4
alkyl, aryl C
2-10
alkenyl, aryloxy, aryl C
1-4
alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl C
2-10
alkenyl, heteroaryl C
1-4
alkyloxy, heterocyclic, heterocyclic C
1-4
alkyl, heterocyclicC
1-4
alkyloxy, heterocyclicC
2-10
alkenyl, (CR
8
R
8
)q NR
4
R
5
, (CR
8
R
8
)qC(O)NR
4
R
5
, C
2-10
alkenyl C(O)NR
4
R
5
, (CR
8
R
8
)q C(O)NR
4
R
10
, S(O)
3
R
8
, (CR
8
R
8
)q C(O)R
11
, C
2-10
alkenyl C(O)R
11
, C
2-10
alkenyl C(O)OR
11
, (CR
8
R
8
)q C(O)OR
11
, (CR
8
R
8
)q OC(O)R
11
, (CR
8
R
8
)qNR
4
C(O)R
11
, (CR
8
R
8
)q C(NR
4
)NR
4
R
5
, (CR
8
R
8
)q NR
4
C(NR
5
)R
11
, (CR
8
R
8
)q NHS(O)
t
R
13
, (CR
8
R
8
)q S(O)
t
NR
Jin Qi
McCleland Brent W.
Palovich Michael R.
Widdowson Katherine L.
Kinzig Charles M.
McCarthy Mary E.
Simon Soma G.
SmithKline Beecham Corporation
Vollano Jean F.
LandOfFree
Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2952899